56 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
and cash equivalents
Short term deposits
Prepaid expenses and other receivables
Total Current Assets
Non-Current Assets
Long term interest-bearing bank …
Accounts payable trade
Accrued expenses and other liabilities
Total Current Liabilities
Non-Current Liabilities
Other long-term liabilities
Total Non
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
Current Liabilities
Non-Current Liabilities
Other long-term Liabilities
Total Non-Current Liabilities
Commitments and Contingent Liabilities
TOTAL … , however, that the Company will be successful in obtaining an adequate level of financing needed for its long-term development. The Company’s ability
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
14 Nov 19
Condensed Consolidated Financial Statements
7:30am
-Current Assets
Restricted cash
Long-term prepaid expenses
Property and equipment, net (note 4)
Other assets (note 6)
Total Non-Current Assets
Total Assets … 1a.)
Related parties
Total Current Liabilities
Non-Current Liabilities
Retirement benefit obligations
Other long-term Liabilities (note 6)
Warrants
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
21 Nov 14
Bio Blast Pharma Reports Third Quarter Financial Results
12:00am
expenses
Total current assets
Long-term assets:
Long-term deposit
Property and equipment, net
Total long-term assets
Total assets
LIABILITIES … and prepaid expenses
Long term deposit
Trade payables
Other accounts payable
Net cash used in operating activities
Cash flow from investing activities
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
expenses and other liabilities
CVR holders
Total Current Liabilities
Non-Current Liabilities
Other long-term Liabilities
Total Non-Current Liabilities … . There are no assurances, however, that the Company will be successful in obtaining an adequate level of financing needed for its long-term development
6-K
EX-99.1
2ko8kgj1 v8uu4
31 Dec 18
Current report (foreign)
4:05pm
6-K
EX-99.1
op36m78mcha eyz6h4
29 Aug 14
BioBlast Pharma Reports Second Quarter Financial Results
12:00am
6-K
EX-99.1
ah9nfasysu05ervsfk
18 Nov 20
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
8:02am
6-K
EX-99.1
l8mz0m2vh0c
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
l80c8prvmfh7l
18 May 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
oh6the57 uyq
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
lmrbnyurafsyixh1y
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
1itjg15khtz4gr
20 May 19
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
bh74d
26 Jul 19
Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
4yx0b3h
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
xvj1414n
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
yint vuyadsp2nk3w
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.1
sqeyx9
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
pkawx31ztm wdn
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K/A
EX-99.1
ivbph2e8nov
13 Oct 20
Condensed Consolidated Financial Statements
9:16am